Cyclotron produced <sup>132</sup>La as a PET imaging surrogate of therapeutic <sup>225</sup>Ac

Aluicio‐Sarduy, Eduardo; Barnhart, Todd E.; Weichert, Jamey P.; Hernandez, Reinier; Engle, Jonathan W.

doi:10.2967/jnumed.120.255794

Cited by 23 publications

(21 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The trio of lanthanum radionuclides 132 La, 133 La and 135 La present an interesting prospect for the fulfilment of the ideal theranostic concept of chemically-identical matching of diagnostic and therapeutic radionuclides (Aluicio-Sarduy et al 2020 ). 132 La (t 1/2 = 4.6 h) is a positron emitter that has garnered interest as a PET imaging radionuclide and has seen applications as a surrogate imaging agent to probe the in vivo biodistribution of 225 Ac due to similarities in their chemical properties (Aluicio-Sarduy et al 2021 ). Likewise, the positron emitter 133 La has also emerged as a PET imaging candidate with the potential to improve the PET imaging quality of metastases and smaller tumours.…”

Section: Lanthanum: 132 La ...mentioning

confidence: 99%

“…Cyclotrons have also been used for the production of 132 La from natural Ba targets via the 132 Ba(p,n) 132 La chemical reaction, in a similar manner to the production of 135 La, for the production of the theranostically relevant 132 La/ 135 La radionuclide pair (Aluicio-Sarduy et al 2021 , 2019 ). However, it has been reported that current production routes to 132 La using natural Ba targets have been hindered by current cyclotron production methods requiring long irradiation times and the relatively low natural abundance of the requisite 132 Ba isotope (0.1% natural abundance) (Nelson et al 2020 ).…”

Section: Lanthanum: 132 La ...mentioning

confidence: 99%

See 1 more Smart Citation

Cutting edge rare earth radiometals: prospects for cancer theranostics

Sadler

Hogan

Fraser

et al. 2022

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

Background With recent advances in novel approaches to cancer therapy and imaging, the application of theranostic techniques in personalised medicine has emerged as a very promising avenue of research inquiry in recent years. Interest has been directed towards the theranostic potential of Rare Earth radiometals due to their closely related chemical properties which allow for their facile and interchangeable incorporation into identical bifunctional chelators or targeting biomolecules for use in a diverse range of cancer imaging and therapeutic applications without additional modification, i.e. a “one-size-fits-all” approach. This review will focus on recent progress and innovations in the area of Rare Earth radionuclides for theranostic applications by providing a detailed snapshot of their current state of production by means of nuclear reactions, subsequent promising theranostic capabilities in the clinic, as well as a discussion of factors that have impacted upon their progress through the theranostic drug development pipeline. Main body In light of this interest, a great deal of research has also been focussed towards certain under-utilised Rare Earth radionuclides with diverse and favourable decay characteristics which span the broad spectrum of most cancer imaging and therapeutic applications, with potential nuclides suitable for α-therapy (149Tb), β−-therapy (47Sc, 161Tb, 166Ho, 153Sm, 169Er, 149Pm, 143Pr, 170Tm), Auger electron (AE) therapy (161Tb, 135La, 165Er), positron emission tomography (43Sc, 44Sc, 149Tb, 152Tb, 132La, 133La), and single photon emission computed tomography (47Sc, 155Tb, 152Tb, 161Tb, 166Ho, 153Sm, 149Pm, 170Tm). For a number of the aforementioned radionuclides, their progression from ‘bench to bedside’ has been hamstrung by lack of availability due to production and purification methods requiring further optimisation. Conclusions In order to exploit the potential of these radionuclides, reliable and economical production and purification methods that provide the desired radionuclides in high yield and purity are required. With more reactors around the world being decommissioned in future, solutions to radionuclide production issues will likely be found in a greater focus on linear accelerator and cyclotron infrastructure and production methods, as well as mass separation methods. Recent progress towards the optimisation of these and other radionuclide production and purification methods has increased the feasibility of utilising Rare Earth radiometals in both preclinical and clinical settings, thereby placing them at the forefront of radiometals research for cancer theranostics.

show abstract

Section: Lanthanum: 132 La ...mentioning

confidence: 99%

Section: Lanthanum: 132 La ...mentioning

confidence: 99%

Cutting edge rare earth radiometals: prospects for cancer theranostics

Sadler

Hogan

Fraser

et al. 2022

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

show abstract

“…Theranostics has strong potential in targeted radionuclide therapy, where a diagnostic positron or gamma-emitting radionuclide used in PET or SPECT is paired with an alpha (α), beta (β -), or Auger electron-emitting therapeutic radionuclide (2). Recently introduced 133 La (t1/2=3.9 h), 132 La (t1/2=4.8 h), and 134 Ce (t1/2=3.2 d)/ 134 La (t1/2=6.5 min) PET radionuclides are uniquely suited as theranostic imaging partners for 225 Ac (t1/2=9.9 d) in targeted alpha therapy (TAT), or with 135 La (t1/2=19.5 h) in Auger electron therapy (AET) due to their chemical similarity and longer half-lives compared to the ubiquitous PET radiometal 68 Ga (t1/2=68 min) (2)(3)(4)(5)(6)(7). Actinium-225 has shown considerable efficacy in clinical trials for treating metastatic cancers (2,8).…”

Section: Introductionmentioning

confidence: 99%

“…Actinium-225 has shown considerable efficacy in clinical trials for treating metastatic cancers (2,8). Lanthanum-132 has been proposed as a theranostic PET imaging surrogate for 225 Ac therapy, and displayed similar in vivo uptake characteristics compared to 225 Ac (6). However, there are fundamental imaging limitations inherent to 132 La due to its high positron emission energy (Emax/Emean=3.67/1.29 MeV) that significantly reduces image spatial resolution and contrast compared to other PET radionuclides (e.g.…”

Section: Introductionmentioning

confidence: 99%

First In Vivo and Phantom Imaging of Cyclotron-Produced ¹³³La as a Theranostic Radionuclide for ²²⁵Ac and ¹³⁵La

et al. 2021

View full text Add to dashboard Cite

Theranostic isotope pairs have gained recent clinical interest as they can be labeled to the same tracer and applied for diagnostic and therapeutic purposes. The goals of this study were to A) investigate cyclotron production of clinically relevant 133 La activities using natural and isotopically enriched barium target material, B) compare fundamental positron emission tomography (PET) phantom imaging characteristics of 133 La with common PET radionuclides, and C) demonstrate in vivo preclinical PET tumor imaging using 133 La-PSMA-I&T. Methods: 133 La was produced on a 24 MeV cyclotron using an aluminum-indium sealed target with 150-200 mg of isotopically enriched 135 BaCO3, nat BaCO3, and nat Ba metal. A NEPTIS Mosaic-LC performed Ba/La separation. DOTA, PSMA-I&T, and macropa were radiolabeled with 133 La.Derenzo and National Electrical Manufacturers Association (NEMA) phantom imaging was performed with 133 La, 132 La, and 89 Zr and compared with 18 F, 68 Ga, 44 Sc, and 64 Cu. In vivo preclinical imaging was performed with 133 La-PSMA-I&T in LNCaP tumor-bearing mice.

show abstract

“…Production using this class of cyclotron was selected since these machines are the most prevalent in medical and research institutions. While the list of radioisotopes reviewed is a comprehensive one, the authors would like to highlight other PET radioisotopes such as 110m In 12,13 , 152 Tb, 13,14 51 Mn, 15,16 62 Cu 16-18 and 132 La 19,20 which are also available for production on the aforementioned cyclotrons, but were excluded from this review due to limitations. This review briey discusses the biomedical application of each radionuclide while focusing mainly on the specics of its production and purication procedures.…”

Section: Introductionmentioning

confidence: 99%